EVALUATION OF THE EFFECT OF LIVER FUNCTION TEST OF BETA & HBE/BETA THALASSAEMIA PATIENTS ON TRANS-RESVERATROL THERAPY Anirban Roy Chowdhury1* , Sudipa Chakravarty2 , Amit Chakravarty 2

Recent studies demonstrated that resveratrol has many therapeutic effects on liver disorders. It significantly increased survival after liver transplantation, decreased fat deposition, necrosis, and apoptosis which induced by ischemia in Wistar rats. It provided liver protection against chemical, cholestatic, and alcohol injury. Resveratrol can improve glucose metabolism and lipid profile and decrease liver fibrosis and steatosis. Furthermore, it was able to alter hepatic cell fatty acid composition. This study we observed the pre-treatment and post-treatment of resveratrol and evaluation of blood CBC parameters in patients with beta and HbE-beta thalassaemia shows three categories of response: Complete Response (52.2%; in patients who can able to maintain at an average Hb level of 6-9 gm/dL without blood transfusion, in this group 12.3% patients are without any previous H/O blood transfusion, others shifted from monthly blood transfusion dependency to a stable transfusion-free condition); Partial Response (18.2%; in patients who remained transfusion dependent but at longer intervals : 2-3 months or more) and Non response (15.9%; in patients who, after more than one year of treatment, remained at the same level of transfusion dependency) and we observed the evaluation of LFT of Beta and Hb E/Beta thalassaemic patients on Trans Resveratrol Therapy. Key words: Resveratrol, β-thalassemia, LFT, Blood transfusion, Good responder, Moderate responder, Non responder.